For research use only. Not for therapeutic Use.
Ipilimumab (Cat.No:I018817) is a monoclonal antibody used in immunotherapy for the treatment of advanced melanoma, a type of skin cancer. It works by targeting and blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which helps activate the immune system against cancer cells. Ipilimumab has shown promising results in extending patient survival and is an important therapy in the field of oncology.
| Catalog Number | I018817 |
| CAS Number | 477202-00-9 |
| Purity | ≥95% |
| Reference | [1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. |
